RAPT Therapeutics Announces Multiple Late-Breaking Presentations at the Upcoming American Association for Cancer Research (AACR) Annual Meeting
05 März 2024 - 10:30PM
RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage,
immunology-based therapeutics company focused on discovering,
developing and commercializing oral small molecule therapies for
patients with significant unmet needs in inflammatory diseases and
oncology, today announced the acceptance of three late-breaking
abstracts for poster presentation, including a poster presentation
for tivumecirnon (FLX475), its lead oncology drug candidate,
highlighting phase 2 clinical data in head and neck squamous cell
carcinoma (HNSCC), at the American Association for Cancer Research
(AACR) Annual Meeting which will take place April 5-10, 2024 in San
Diego, CA.
Late-breaking poster presentation details:
Title: |
|
Phase 2 Study of Oral CCR4 Antagonist FLX475 (tivumecirnon) Plus
Pembrolizumab in Subjects with Head and Neck Squamous Cell
Carcinoma (HNSCC) Previously Treated with Checkpoint Inhibitor |
Abstract
Number: |
|
CT226 |
Date &
Time: |
|
Tuesday, April 9, 2024; 9:00 a.m.
– 12:30 p.m. PT |
Session
Title: |
|
Phase II Clinical Trials 1 |
Location: |
|
Poster Section 49 |
Title: |
|
A
Combined mregDC and Treg Signature Associates with Antitumor
Efficacy of CCR4 Antagonist Tivumecirnon FLX475 |
Abstract
Number: |
|
2485 |
Date &
Time: |
|
Monday, April 8, 2024; 9:00 a.m.
- 12:30 p.m. PT |
Session
Title: |
|
Predictive Biomarkers 1 |
Location: |
|
Poster Section 43 |
Title: |
|
HPK1 inhibits CD8+ T cell effector gene expression following T cell
activation |
Abstract
Number: |
|
2654 |
Date &
Time: |
|
Monday, April 8, 2024; 1:30 -
5:00 p.m. PT |
Session
Title: |
|
Immune Checkpoints and Inhibitory
Molecules 2 |
Location: |
|
Poster Section 4 |
|
|
|
Late-breaking abstract titles are currently
available on AACR’s online itinerary planner, and late-breaking
abstract text will be available on AACR’s planner on April 5, 2024
at 12:00 p.m. PT. The planner can be accessed at:
https://www.abstractsonline.com/pp8/#!/20272.
About RAPT Therapeutics, Inc.
RAPT Therapeutics is a clinical-stage,
immunology-based therapeutics company focused on discovering,
developing and commercializing oral small molecule therapies for
patients with significant unmet needs in inflammatory diseases and
oncology. Utilizing its proprietary discovery and development
engine, the Company is developing highly selective small molecules
designed to modulate the critical immune drivers underlying these
diseases. RAPT has discovered and advanced two unique drug
candidates, zelnecirnon (RPT193) and tivumecirnon (FLX475), each
targeting C-C motif chemokine receptor 4 (CCR4), for the treatment
of inflammation and cancer, respectively. The Company is also
pursuing a range of targets that are in the discovery stage of
development.
RAPT Media Contact:Aljanae
Reynoldsareynolds@wheelhouselsa.com
RAPT Investor Contact:Sylvia
Wheelerswheeler@wheelhouselsa.com
RAPT Therapeutics (NASDAQ:RAPT)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
RAPT Therapeutics (NASDAQ:RAPT)
Historical Stock Chart
Von Mai 2023 bis Mai 2024